MedDataX Logo

Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose

NCT ID: NCT00507013

Last Updated: 2008-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The QuickClose study is a prospective, non-randomized study, to evaluate the safety and efficacy of the QuickClose device using two different dose types of heat exposure.

Patients undergoing a diagnostic angiogram procedure will be treated with the QuickClose device. Two groups of 20 patients each, will be enrolled consecutively, Group A will complete enrollment before enrollment into Group B begins. Patients will be monitored until 30 days after the procedure

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary safety endpoint is the incidence of major complications related to method for achieving hemostasis at the puncture site. The secondary safety endpoint is the incidence of minor complications related to method for achieving hemostasis at the puncture site. The primary efficacy endpoint are time to hemostasis, time to ambulation and time to discharge . The secondary efficacy endpoints are device and procedure success.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemostasis,Surgical

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

vascular closure device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

Group Type OTHER

QuickClose device

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QuickClose device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient must be ≥ 18 years of age
2. The patient or guardian must provide written informed consent
3. The patient must be willing to comply with follow-up requirements
4. The patient has no child bearing potential or has a negative pregnancy test within the previous 7 days.
5. Patient is eligible for same day discharge

Procedural Inclusion:

1. A intravascular procedure was preformed using 6 Fr introducer
2. The introducer sheath is located in the common femoral artery

Exclusion Criteria

1. Manual compression has been preformed on the ipsilateral arterial site within the previous 6 weeks
2. Any closure device has been used on the ipsilateral arterial site within the previous 180 days
3. Any reentry of the ipsilateral site is planned within the next 6 weeks.
4. History of surgical repair of blood vessels of the ipsilateral arterial site
5. Significant bleeding diathesis or platelet dysfunction

1. Thrombocytopenia (Plt count ≤ 100,000)
2. Anemia (Hgb ≤ 10mg/dl and/or Hct ≤ 30mg/dl)
6. Has life expectancy of less than 1 year due to terminal illness
7. Currently being treated for an infection
8. Receiving GP 2b/3a inhibitors or requires warfarin therapy within the last 14 days.
9. INR results \> 1.2 on day of procedure
10. Experienced a Myocardial infarction (CK-MB ≥ 2x upper limits of normal) within the previous 72 hours
11. Received thrombolytic within previous 72 hours
12. Patient is currently enrolled in an investigational device or drug study which endpoints have not been met.
13. Absent of pedal pulse
14. Pre-existing autoimmune disease (i.e., Lupus, Addison's Disease, Grave's Disease)
15. Has Body Mass Index(BMI) \<20, or BMI \>40
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sheba Medical Center

OTHER_GOV

Sponsor Role collaborator

CardioDex

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amit Segev, MD

Role: PRINCIPAL_INVESTIGATOR

The Chaim Sheba Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Chaim Sheba M.C.

Tel Litwinsky, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD 392-03

Identifier Type: -

Identifier Source: org_study_id